Paid Clinical Trials for Minimal Residual Disease

Login to your account

Reset Password

Please Enter Username or Email

Create a free account

I'm a Participant
I'm an Organization

Showing all 4 results

Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease

by CTG

in Minimal Residual Disease, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive

Other

Alaska

Deadline:

08/31/2031

A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

by CTG

in Fruquintinib, Adjuvant Chemotherapy, Minimal Residual Disease, Colorectal Cancer, Tislelizumab

Other

Texas

Deadline:

04/01/2028

Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)

by CTG

in Minimal Residual Disease, Colorectal Cancer

Other

Texas

Deadline:

01/18/2029

Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults w/ Recurrent or Refractory B Cell Malignancies

by CTG

in Minimal Residual Disease, CD19 Positive, Philadelphia Chromosome Positive, B Acute Lymphoblastic Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia

Other

California

Deadline:

08/01/2035